Instituut voor Neuropathische Pijn

Home

Raptor Pharma's NGX426 voor neuropathische pijn

Raptor Pharmaceuticals Corp. ontwikkelt de stof NGX426 voor neuropathische pijn. Het bedrijf meldde op 21 november 2009 dat resultaten van een kleine fase II studie lieten zien dat 150 mg van de stof effectief was. In het persbericht lezen we:

A single center, double-blind, randomized study conducted in 18 subjects compared the effectiveness of 90 mg, 150 mg of NGX426 in pain reduction, 30 and 120 minutes after inducing the pain with a capsaicin injection.

Results reveal that 150 mg of the compound was statistically significant in reducing spontaneous and elicited pain, after both time intervals.

90 mg NGX426, on the other hand, significantly reduced spontaneous pain, hyperalgesia or increased pain sensitivity and allodynia or pain due to an abnormal stimulus, after 30 minutes. After 120 minutes, the dosage was effective against hyperalgesia and allodynia, compared with placebo.

NGX426 ie een oraal in te nemen prodrug van tezampanel en was eerder voorzien als een middel tegen migraine. In een eerder persbericht lezen we over de resultaten bij migraine:

"These findings with the oral form of tezampanel are very encouraging, especially when looked at in conjunction with the data from our evaluation of the subcutaneous form," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines Therapeutics.

"These data fully support the continued development of NGX426, which, as an oral prodrug, can provide an additional route of administration for tezampanel to acute migraine sufferers."

Dat was in 2007, dus de ontwikkeling van deze stof begon in de indicatie miraine.

Tezampanel is een 'non-N-methyl-d-aspartate receptor antagonist' ^[1] De stof wordt ook wel gekarakteriseerd als een AMPA/kainate-type glutamate receptor antagonist. De CEO van de company merkte op dat:

"We are very encouraged by these results that show an analgesic effect for NGX426 in this well-accepted pain model," said Ev Graham, Chief Executive Officer of TorreyPines. "As an oral, non-opioid pain agent, NGX426 could address the significant and documented unmet needs in treating a range of chronic pain conditions including neuropathic pain and acute or prophylactic treatment of migraine. These data, as well as data from our on-going Phase I multiple dose trial, will help us structure our Phase II development plan for NGX426."

De voorloper van de orale versie is ontdekt door Eli Lilly.

November 2009: prof.dr. Jan M. Keppel Hesselink

Referenties

[1]: Jin HC, Keller AJ, Jung JK, Subieta A, Brennan TJ. | Epidural tezampanel, an AMPA/kainate receptor antagonist, produces postoperative analgesia in rats. | Anesth Analg. | 2007 Oct;105(4):1152-9, table of contents.